Gavi Expanding Sustainable Vaccine Manufacturing in Africa 2022
WHITE PAPER | 2 November 2022
The pandemic has highlighted new and pressing challenges to regional vaccine supply resilience as a critical factor in global health security. While 1.8 billion doses1 of COVID-19 vaccine have been shipped under COVAX, including 0.6 billion to Africa, early delays in obtaining doses on the African continent stimulated new resolve to address future supply security.
COVAX: key learnings for future pandemic preparedness and response
WHITE PAPER | 14 September 2022
Drawing on COVAX’s unique experience enabling an unprecedented global rollout at scale during a pandemic, this paper outlines the key challenges the mechanism faced in seeking to ensure equitable access to COVID-19 vaccines, the actions it took in response and recommendations for the future.
A New Era of Vaccine Manufacturing in Africa
WHITE PAPER | 22 June 2022
One of the prominent issues exposed by the COVID-19 pandemic is the urgent need to further diversify global vaccine manufacturing, particularly with regards to Africa. With the political realities of nationalism, trade barriers, and the absence of regional manufacturing capability and capacity, rapid and equitable global access to life-saving vaccines can be compromised, leading to delays that put lives at risk.
Taking stock of humanitarian access to pandemic vaccines
DISCUSSION PAPER | 22 June 2022
COVAX was launched in 2020 with equity as its foundational principle, and fundamental to its design from the outset was a vision to address the most unpredictable and hardest to fill gaps in global COVID-19 vaccine access.
All Products
Last updated: 29 Nov 2022